1-3 of 3
Kevin J. Harrington
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients

Adel Samson, Emma J. West, Jonathan Carmichael, Karen J. Scott, Samantha Turnbull, Bethany Kuszlewicz, Rajiv V. Dave, Adam Peckham-Cooper, Emma Tidswell, Jennifer Kingston, Michelle Johnpulle, Barbara da Silva, Victoria A. Jennings, Kaidre Bendjama, Nicolas Stojkowitz, Monika Lusky, K.R. Prasad, Giles J. Toogood, Rebecca Auer, John Bell, Chris J. Twelves, Kevin J. Harrington, Richard G. Vile, Hardev Pandha, Fiona Errington-Mais, Christy Ralph, Darren J. Newton, Alan Anthoney, Alan A. Melcher, Fiona Collinson
Journal: Cancer Immunology Research
Cancer Immunol Res (2022) 10 (6): 745–756.
https://doi.org/10.1158/2326-6066.CIR-21-0171
Published: 03 June 2022
View articletitled, Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Open the PDF for Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients in another window
Includes: Supplementary data
Journal Articles

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

Laura Evgin, Amanda L. Huff, Timothy Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett, Karen Kaluza Smith, Reuben S. Harris, Matt Coffey, Jose S. Pulido, Hardev Pandha, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Richard G. Vile
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (5): 828–840.
https://doi.org/10.1158/2326-6066.CIR-18-0013
Published: 01 May 2019
View articletitled, Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Open the PDF for Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment in another window
Includes: Supplementary data
Journal Articles

Abstract A133: APOBEC3 confers resistance to oncolytic VSV therapy

Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy Molan, Jose S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard Vile
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (2_Supplement): A133.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR18-A133
Published: 01 February 2019
View articletitled, Abstract A133: APOBEC3 confers resistance to oncolytic VSV therapy